Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India

Clinical Infectious Diseases

Volumn 38, Issue 2, 2004, Pages 217-221

  Bhattacharya, Sujit K ^a   Jha, T K ^c   Sundar, Shyam ^c   Thakur, C P ^b   Engel, Juergen ^d   Sindermann, Herbert ^d   Junge, Klaus ^d   Karbwang, Juntra ^e   Bryceson, Anthony D M ^f   Berman, Jonathan D ^g,h  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b Balaji Utthan Sansthan   (India)

^c Kala azar Research Centre   (India)

^d Zentaris GmbH   (Germany)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h National Institutes of Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; MILTEFOSINE;

ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARAMETER; PARASITOLOGY; PATIENT; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 9144229462     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380638     Document Type: Article

References (27)

1. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and proposed research and development agenda. Lancet Infectious Diseases 2002; 2:494-501.
2. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12:62-8.
3. World Health Organization (WHO). Dramatic upsurge in visceral leishmaniasis cases in the Horn of Africa [press release]. Geneva: WHO, 13 February 1998.
4. Desjeux P. Information on the epidemiology and control of the leishmaniasis by country or territory. WHO/LEISH/91.30. Geneva: World Health Organization, 1991:36.
5. Jha SN, Singh NKP, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonials. J Assoc Physicians India 1991; 39:314-6.
6. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77:167-70.
7. Thakur CP, Sinha GP, Barat D, et al. Two hours versus six hours administration of amphotericin B in the treatment of kala-azar. Intl J Antimicrob Agents 1995; 5:115-7.
8. Berman JD. Editorial response: US FDA approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:49-51.
9. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36:1630-4.
10. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
11. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93:589-97.
12. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
13. Sundar S, Makharia A, More DK, et al. Short course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-3.
14. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
15. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434-8.
16. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475-9.
17. Cancer Therapy Evaluation Program. Common toxicity criteria. Rockville, MD: National Cancer Institute, 2002. Available at: http:// ctep.cancer.gov/ reporting/index.html. Accessed on 7 December 2003.
18. Meyerhoff A. US FDA approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42-8.
19. World Health Organization (WHO). The treatment of diarrhoea - a manual for physicians and other senior health workers. Diarrhoeal Diseases Control Programme (CDD). WHO/CDR/95.3. Geneva: WHO, 1995.
20. Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK. Amphotericin B in resistant kala-azar in Bihar. Natl Med J India 1993; 6:57-60.
21. Hashim FA, Ali MS, Satti M, et al. An outbreak of acute kala-azar in a nomadic tribe in western Sudan: features of the disease in a previously non-immune population. Trans R Soc Trop Med Hyg 1994; 88:431-2.
22. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800-4.
23. Zentaris AG. Impavido registration certificate for miltefosine capsules 10 mg and 50 mg. Issued by Drug Controller General India. 15 March 2002.
24. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928-34.
25. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 1999; 13:1063-9.
26. Thakur CP, Sinha PK, Singh RK, et al. Miltefosine in a case of visceral leishmaniasis with HIV co-infection, and rising incidence of this disease in India. Trans R Soc Trop Med Hyg 2000; 94:696-7.
27. Sinha PK, Rabidas VN, Pandey K, et al. Visceral leishmaniasis and HIV coinfection in Bihar, India. J Acquir Immune Defic Syndr 2003; 32:115-6.